Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Option Care Health closed Tuesday at $31.00, up 36% on the week. The move forced a wave of analyst downgrades on the same day, creating one of the starker disconnects in health care services this year: the stock re-rated sharply higher while the Street's conviction in its growth story fell lower.
The analyst action on October 7 was unusually concentrated. JP Morgan's Lisa Gill downgraded from Overweight to Neutral with a $33 target. Jefferies cut from Buy to Hold, simultaneously raising its target from $28 to $32.05. Barrington Research and Citizens both moved to Market Perform. The direction of travel was unanimous, four firms pulling back in a single session, all on the same day the stock printed its biggest weekly gain in years. The mean price target across the consensus now sits at $30.39, fractionally below Tuesday's close of $31.00, which tells you how little room the Street sees above current levels. The consensus itself is a hold, with nine hold-rated analysts against just two with more constructive views.
The bear case has a clear shape. Management's guided EBITDA headwind from the CID/Stelara situation widened to $55 million, up from an earlier estimate of $25 million to $35 million. Second-quarter adjusted EBITDA guidance of $112 million to $115 million fell well short of the $122 million consensus. Revenue of $1.35 billion grew only 1.3% year over year and missed estimates by around $40 million. The implied second-half EBITDA ramp, where 55% to 57% of full-year earnings need to come through, looks demanding against a four-year average of 52% to 53%. Bulls still point to durable demand in acute therapies, a high-single-digit growth profile in that segment, and management's insistence that Stelara and biosimilars will represent less than 1% of 2026 revenue and gross profit. The EV/EBITDA multiple has expanded by around 2.2 points over the past 30 days as the stock ran, now sitting at 11.1x, a meaningful re-rating for a business with near-term earnings pressure. Factor scores reinforce the cautious read: short score ranks in the 29th percentile, dividend score in the 29th, with only the EV/EBIT multiple scoring well at the 73rd percentile.
The lending market shows no sign of stress despite the sharp move. Short interest is 6.9% of the free float, down about 4.3% over the past month, meaning bears were actually covering into the rally rather than pressing. Borrow availability is extremely loose at 1,286%, with 130 million shares available against roughly 11 million sold short. Cost to borrow is just 0.47%, having drifted lower over the past month. The short score itself dropped to 45.7 from above 50 two weeks ago, consistent with bears reducing rather than building pressure. The ORTEX Alt Data layer flags a Wikipedia attention spike with a z-score of 5.65 against the prior 90 days, reflecting heightened retail attention around the price move, though that dataset has not been measured to lead the company's financial figures. Options positioning is neutral to slightly call-heavy, with the put/call ratio at 0.13, near its 20-day average and well below the 52-week high of 0.87, suggesting options traders are not hedging into the move.
On the ownership side, Wellington Management remains the largest disclosed holder at around 7.9% of shares, though its 13G/A filing from August 2025 showed a reduction from 10.0% to 8.1%. Durable Capital Partners filed an amendment showing a drop from 5.0% to 3.9% in August, falling below the threshold where further filing is required. Passive flows from Vanguard and State Street have been broadly stable. The insider data is stale, with the most recent Form 4 transactions dating to early July when compensation grants were recorded, there have been no open-market purchases or sales from C-suite executives on file in the relevant window.
Q3 results are due October 29, 22 days from now. The prior two prints produced small negative day-one reactions, down 3.8% in April and essentially flat in July, with modest five-day recoveries in the latter case. With the stock up 36% in a week, the question heading into that print is whether the move has pulled forward any recovery multiple before the company has had a chance to demonstrate whether the EBITDA ramp demanded in the second half is actually materialising.
See the live data behind this article on ORTEX.
Open OPCH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
